The effect of Aryl hydrocarbon receptor (AHR) inhibitor CH-223191 on differentiation of human colon organoids
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 12 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Dysregulation of the Environmental Sensor Aryl Hydrocarbon Receptor Affects Differentiation of Human Colon OrganoidsCellular and molecular gastroenterology and hepatology · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE229116_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA952947 and SRA study SRP431296. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 12 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7152796 104 differentiated CH-223191 treated lane 1 104 differentiated CH-2…
- GSM7152797 104 differentiated CH-223191 treated lane 2 104 differentiated CH-2…
- GSM7152798 104 differentiated DMSO treated lane 1 104 differentiated DMSO…
- GSM7152799 104 differentiated DMSO treated lane 2 104 differentiated DMSO…
- GSM7152800 104 stem cell condition CH-223191 treated lane 1 104 stem cell condition…
- GSM7152801 104 stem cell condition CH-223191 treated lane 2 104 stem cell condition…
- GSM7152802 104 stem cell condition DMSO treated lane 1 104 stem cell condition…
- GSM7152803 104 stem cell condition DMSO treated lane 2 104 stem cell condition…
- GSM7152804 134 differentiated CH-223191 treated lane 1 134 differentiated CH-2…
- GSM7152805 134 differentiated CH-223191 treated lane 2 134 differentiated CH-2…
- GSM7152806 134 differentiated DMSO treated lane 1 134 differentiated DMSO…
- GSM7152807 134 differentiated DMSO treated lane 2 134 differentiated DMSO…
- GSM7152808 134 stem cell condition CH-223191 treated lane 1 134 stem cell condition…
- GSM7152809 134 stem cell condition CH-223191 treated lane 2 134 stem cell condition…
- GSM7152810 134 stem cell condition DMSO treated lane 1 134 stem cell condition…
- GSM7152811 134 stem cell condition DMSO treated lane 2 134 stem cell condition…
- GSM7152812 193 differentiated CH-223191 treated lane 1 193 differentiated CH-2…
- GSM7152813 193 differentiated CH-223191 treated lane 2 193 differentiated CH-2…
- GSM7152814 193 differentiated DMSO treated lane 1 193 differentiated DMSO…
- GSM7152815 193 differentiated DMSO treated lane 2 193 differentiated DMSO…
- GSM7152816 193 stem cell condition CH-223191 treated lane 1 193 stem cell condition…
- GSM7152817 193 stem cell condition CH-223191 treated lane 2 193 stem cell condition…
- GSM7152818 193 stem cell condition DMSO treated lane 1 193 stem cell condition…
- GSM7152819 193 stem cell condition DMSO treated lane 2 193 stem cell condition…
- GSE250196 Endogenous aryl hydrocarbon receptor ligands-dysregulated transcriptomic profiles and endothelial function in human fetal endothelial cells 22 samples shares hydrocarbon, receptor, aryl
- GSE305296 Activation of the aryl hydrocarbon receptor in human melanoma cells enhances cancer cell-intrinsic MHC-II expression 43 samples shares hydrocarbon, receptor, aryl
- GSE222196 Treatment of prostate cancer cell lines with Androgen Receptor and Receptor Tyrosine Kinase inhibitors 246 samples shares inhibitor, receptor
- GSE284956 Overcoming intrinsic mechanisms of cell cycle inhibitor resistance in estrogen receptor-positive (ER+) breast cancer 180 samples shares inhibitor, receptor
- GSE240497 Activation of a nongenetic AHR-ELMSAN1 axis optimizes BET-targeting therapy and suppresses leukemia stem cells in preclinical models 66 samples shares ahr
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares inhibitor
- GSE287540 Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury [bulk RNA-seq] 128 samples shares inhibitor
- GSE305224 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [RNA-seq] 120 samples shares inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.